PEACCEL at glance
December 2nd, 2024
Making the world
disease free
We find the real drug
lead candidate by
capturing the synergistic effect of
mutations (epistasis)
We have developed the
innov’SAR AI platform
for our partners.
The innov’SAR core approach is interpolative, extrapolative and predicts out-of-the-box, not found in other state-of-the-art ML / DL. It can screen 1 Billion mutants per day.
PEACCEL is definitely the only company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of “hit rate”.
PEACCEL's world-class
Data Scientists in Life Sciences
History
2024
Awarded DeepTech Label by BPI France
Quantum Computing for Biologics
2021-2023
Patent on proprietary molecules
AI Platform for Biologics 3.0
Technology Patents Worldwide
Awards Winner in Artificial Intelligence for Life Sciences
2018-2020
Contracts with key players in chemical industry
innov'SAR integrated platform for Protein Engineering & Fixed Drugs Combinations (FDCs)
€2m competitive EU funds
First contracts with key pharmaceuticals companies
2017
innov’SAR core launch
Technology patent delivered by EPO
Presence in Boston, MA, USA
Contract with FDA (USA)
Acquisition of a supercomputer: screening capacity >1Billion mutants/day
End of 2016
€1m seed money
Paris office, France
Artificial Intelligence, Machine Learning, Deep Learning, Quantum Computing, Biotechnology, Pharmaceuticals, Chemistry
PEACCEL is built around the 6 pillars - P6 - :
Platform | Publications | Patents | Partnership | Products | People
RAS module
AutomISAR
GraphMut
The company operates in Paris (France) and Cambridge (MA, USA).